CDC Review Finds Ceftriaxone Anaphylaxis Often Presents Without Rash in Outpatient Settings
核心洞察
A CDC (搜索)-led investigation of 31 severe ceftriaxone reactions across 18 states found that 65 percent of anaphylaxis (搜索)-type cases occurred without skin or mucosal involvement, complicating rapid recognition.
Twelve patients died and 19 received successful CPR; most cases arose in outpatient facilities, and 21 of 31 patients had previously tolerated ceftriaxone without incident.
FDA product testing found no tampering, adulteration, endotoxin, or purity problems, and national adverse event trends remained stable from 2016 through 2024.
A federal review of severe reactions following injections of ceftriaxone, one of the most widely used antibiotics in American clinics and hospitals, has produced a striking clinical finding: most of the anaphylaxis (搜索)-type reactions documented in the investigation did not produce the visible signs clinicians and patients are trained to look for. Among 31 cases identified in a CDC (搜索)-led investigation, 23 involved anaphylaxis-type presentations, and in 65 percent of those there was no skin or mucosal involvement—no hives, no rash, no swelling of the lips or face.
The findings were published in Clinical Infectious Diseases and summarized by CIDRAP News. The work was led by Rebecca Pierce, PhD, of the CDC (搜索)'s Division of Healthcare Quality Promotion, with the Alabama Department of Public Health, other state health departments, and the FDA.
That detail carries practical weight. Anaphylaxis (搜索) without skin signs is harder to recognize quickly, both for the patient and for the staff monitoring them, and speed of recognition drives whether epinephrine is given in time.
Most Cases Occurred in Outpatient Settings
The 31 cases came from 27 health care facilities across 18 states, and 65 percent of those facilities were outpatient. This was not primarily a hospital phenomenon. Ceftriaxone is routinely given in primary care offices, urgent care centers, and emergency departments, most often for respiratory infections, which accounted for 42 percent of the indications among these patients.
The investigation began in December 2024 after an Alabama county coroner reported two unexpected deaths immediately following ceftriaxone injections at two separate primary care clinics within a single week. The Alabama health department then received a report of a third death in a hospitalized patient, plus two nonfatal events. In February 2025, the CDC (搜索) issued a national call for reports of any otherwise unexplained death or successful CPR within six hours of a ceftriaxone injection outside intensive care.
Of the 31 cases meeting that definition, 12 patients died, and 19 received successful CPR. The median age was 67, with an interquartile range of 60 to 81. The cases were identified over the period from September 2024 to August 2025.
The setting matters because monitoring practice varies. Hospitals typically have resuscitation equipment immediately at hand. A small clinic administering an injection may not routinely observe a patient afterward, and there is no universal required observation period following an antibiotic shot the way there is for some allergy treatments.
Prior Doses Offered No Protection
Twenty-one of the 31 patients had received ceftriaxone previously without incident. That undercuts a common intuition that a first dose carries the highest risk, and later doses are safer.
Cardiac conditions were the most consistent shared feature. Twenty-four of the 31 patients had cardiac comorbidities, and antihypertensive use was documented in 19 of the 28 patients with information available. Beta-blockers (搜索) were the most commonly reported medication, taken by 61 percent of patients. That class of blood pressure drug can blunt the body's response to epinephrine, the first-line treatment for anaphylaxis (搜索), and make a severe reaction harder to reverse.
No Evidence of a New Safety Issue
The investigators were direct about what they did not find. Product testing by the FDA found no evidence of tampering, adulteration, endotoxin, or purity and potency problems. Analyses of Medicare claims and a national adverse drug event surveillance system showed stable trends across 2016 through 2019 and 2020 through 2024. The authors wrote that product testing and trend analyses "did not identify evidence of a new safety issue," and that the initial Alabama deaths may represent a chance clustering of known severe reactions.
An accompanying editorial commentary in the same journal, titled "A Signal Without an Answer," by Santiago Alvarez-Arango, MD, PhD, of the University of Texas Southwestern Medical Center in Dallas and Elizabeth J. Phillips, MD, of Vanderbilt University Medical Center, frames the episode around the limits of what a public health investigation can resolve.
Perspective for the Millions Who Receive This Injection
Ceftriaxone is given to a large number of patients every year, and 31 severe cases across a full year of national reporting is a very small number against that denominator. National surveillance data showed no increase over nearly a decade. Nobody should refuse a medically indicated antibiotic based on this report.
The finding is more useful as a recognition prompt than as a reason for alarm. Symptoms of anaphylaxis (搜索) can include difficulty breathing, wheezing, throat tightness, a sudden drop in blood pressure, dizziness or fainting, a rapid pulse, nausea or vomiting, and a sense that something is badly wrong, and these can occur without any rash. Onset is typically within minutes.
The patients at highest risk in this dataset were older adults with existing cardiac conditions, particularly those on blood pressure medication. A reasonable step for anyone in that group receiving an injection in a clinic is to ask whether the office wants them to wait and be observed before leaving, and to tell staff immediately about any symptom that develops during that window.
Anyone experiencing difficulty breathing, throat tightness, or collapse after an injection needs emergency care. That is a call to 911, not a call to a clinic line.
Several questions remain open. The investigation did not establish why these particular patients reacted, whether the cardiac and antihypertensive pattern reflects true added risk or the underlying age of the population, or whether observation periods after outpatient injections should change. The authors called for continued vigilance and for reporting of serious adverse events to the FDA's MedWatch program. No new federal guidance has been issued, and clinicians have not been told to change prescribing.